NNC 63-0532

NNC 63-0532
Clinical data
Other names	NNC 63-0532
Identifiers
	IUPAC name methyl [8-(1-naphthylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl)acetate;
CAS Number	250685-44-0 ;
PubChem CID	9803475 ;
ChemSpider	7979235 ;
UNII	73663SY1DT ;
CompTox Dashboard (EPA)	DTXSID40397885 ;
Chemical and physical data
Formula	C27H29N3O3
Molar mass	443.547 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES c3ccccc3N(CN(C2=O)CC(=O)OC)C2(CC4)CCN4Cc5c1ccccc1ccc5;
	InChI InChI=1S/C27H29N3O3/c1-33-25(31)19-29-20-30(23-11-3-2-4-12-23)27(26(29)32)14-16-28(17-15-27)18-22-10-7-9-21-8-5-6-13-24(21)22/h2-13H,14-20H2,1H3; Key:AQMPIDSGLFVVPL-UHFFFAOYSA-N;
	(verify)

Last updated January 11, 2026

NNC 63-0532 is a nociceptoid drug used in scientific research. It acts as a potent and selective agonist for the nociceptin receptor, also known as the ORL-1 (opiate receptor-like 1) receptor.^[1]^[2]

The function of this receptor is not well understood, but it is believed to play a role in disorders like pain, drug addiction, opioid tolerance development, and psychological disorders such as anxiety and depression. Research into the function of this receptor is an important focus of current pharmaceutical development, and selective agents such as NNC 63-0532 are essential for this work.^[3]

References

↑ Thomsen C, Hohlweg R (November 2000). "(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist". British Journal of Pharmacology. 131 (5): 903–8. doi:10.1038/sj.bjp.0703661. PMC 1572417 . PMID 11053209.
↑ Guerrini R, Carra' G, Calo' G, Trapella C, Marzola E, Rizzi D, et al. (June 2004). "Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity". The Journal of Peptide Research. 63 (6): 477–84. doi: 10.1111/j.1399-3011.2004.00157.x . PMID 15175020.
↑ Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP (January 2007). "Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications". Current Drug Targets. 8 (1): 117–35. doi:10.2174/138945007779315605. PMID 17266536.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Thomsen C, Hohlweg R (November 2000). "(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist". British Journal of Pharmacology. 131 (5): 903–8. doi:10.1038/sj.bjp.0703661. PMC 1572417 . PMID 11053209.

[pmid15175020-2] Guerrini R, Carra' G, Calo' G, Trapella C, Marzola E, Rizzi D, et al. (June 2004). "Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity". The Journal of Peptide Research. 63 (6): 477–84. doi: 10.1111/j.1399-3011.2004.00157.x . PMID 15175020.

[3] Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP (January 2007). "Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications". Current Drug Targets. 8 (1): 117–35. doi:10.2174/138945007779315605. PMID 17266536.

[1]

[2]

[3]